GVHD, Acute
5
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
20.0%
1 terminated out of 5 trials
80.0%
-6.6% vs benchmark
20%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (5)
To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT